Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Neurol India ; 72(2): 358-363, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38691482

ABSTRACT

BACKGROUND: Levetiracetam is the most commonly used antiepileptic drug in pregnant women due to its low teratogenic risk profile, favorable pharmacokinetic characteristics, and safety profile. Serum levels of levetiracetam vary in epilepsy during pregnancy. Therefore, the aim of the study was to evaluate the serum levels of levetiracetam during different trimesters of pregnancy by using therapeutic drug monitoring (TDM). MATERIALS AND METHODS: This was a single-center, prospective study. Pregnant women with epilepsy on levetiracetam were enrolled after getting written informed consent from them. Serum trough levels of levetiracetam were estimated at all trimesters by high-performance liquid chromatography (HPLC). RESULTS: The study included 16 participants with mean ± standard deviation (SD) age of 27.75 ± 4 years. There were nine (56.2%) participants with generalized seizure disorder and seven (43.8%) participants of focal seizure disorder. Among 16 patients, 10 (62.5%) participants were on levetiracetam alone and six (37.5%) participants were on levetiracetam combined with other antiepileptic drugs. In a total of 48 trough samples, 45 sample concentrations were below the therapeutic range of 12-46 mg/l and three sample concentrations were within the therapeutic range. There was a statistically significant difference in the concentration-dose ratio (CDR) of levetiracetam between the third and first trimesters (P-value 0.018). CONCLUSION: There was a statistically significant difference in serum levetiracetam concentration between the third and first trimesters. A well-conducted, intensive pharmacokinetic sampling study in PWWE with a control group is needed in future to evaluate the whole pharmacokinetic profile of levetiracetam and to correlate the clinical outcome.


Subject(s)
Anticonvulsants , Drug Monitoring , Epilepsy , Levetiracetam , Tertiary Care Centers , Humans , Levetiracetam/pharmacokinetics , Levetiracetam/blood , Levetiracetam/therapeutic use , Female , Anticonvulsants/pharmacokinetics , Anticonvulsants/blood , Anticonvulsants/therapeutic use , Pregnancy , Drug Monitoring/methods , Adult , Epilepsy/drug therapy , Epilepsy/blood , Prospective Studies , Young Adult , Pregnancy Trimesters/blood , Pregnancy Complications/drug therapy , Pregnancy Complications/blood , Piracetam/analogs & derivatives , Piracetam/blood , Piracetam/pharmacokinetics , Piracetam/therapeutic use
2.
Article in English | MEDLINE | ID: mdl-38762161

ABSTRACT

OBJECTIVE: Increasing evidence suggests that the physiological changes of pregnancy may impact pharmacokinetics of antiseizure medications (ASM), and this may affect treatment outcomes. The aim of this study was to quantify the pregnancy impact on the ASM pharmacokinetics. METHODS: A systematic literature search was conducted in PubMed/EMBASE in November 2022 and updated in August 2023 for studies comparing levels of ASM in the same individuals during pregnancy and in the preconception/postpartum period. Alteration ratios between the 3rd trimester and baseline were estimated. We also performed a random-effects meta-analysis calculating between-timepoint differences in mean differences (MDs) and 95% confidence intervals (95%CIs) for dose-adjusted plasma concentrations (C/D ratios). Study quality was assessed using the ClinPK guidelines. RESULTS: A total of 65 studies investigating 15 ASMs in 674 pregnancies were included. The largest differences were reported for lamotrigine, oxcarbazepine and levetiracetam (alteration ratio 0.42, range 0.07-2.45, 0.42, range 0.08-0.82 and 0.52, range 0.04-2.77 respectively): accordingly, C/D levels were lower in the 3rd trimester for lamotrigine, levetiracetam and the main oxcarbazepine metabolite monohydroxycarbazepine (MD = -12.33 × 10-3, 95%CI = -16.08 to -8.58 × 10-3 (µg/mL)/(mg/day), p < 0.001, MD = -7.16 (µg/mL)/(mg/day), 95%CI = -9.96 to -4.36, p < 0.001, and MD = -4.87 (µg/mL)/(mg/day), 95%CI = -9.39 to -0.35, p = 0.035, respectively), but not for oxcarbazepine (MD = 1.16 × 10-3 (µg/mL)/(mg/day), 95%CI = -2.55 to 0.24 × 10-3, p = 0.10). The quality of studies was acceptable with an average rating score of 11.5. CONCLUSIONS: Data for lamotrigine, oxcarbazepine (and monohydroxycarbazepine) and levetiracetam demonstrate major changes in pharmacokinetics during pregnancy, suggesting the importance of therapeutic drug monitoring to assist clinicians in optimizing treatment outcomes.


Subject(s)
Anticonvulsants , Humans , Pregnancy , Anticonvulsants/pharmacokinetics , Anticonvulsants/blood , Female , Pregnancy Complications/drug therapy , Levetiracetam/pharmacokinetics , Lamotrigine/pharmacokinetics , Lamotrigine/blood , Epilepsy/drug therapy , Epilepsy/blood , Oxcarbazepine/pharmacokinetics
3.
Epilepsy Res ; 202: 107332, 2024 May.
Article in English | MEDLINE | ID: mdl-38518434

ABSTRACT

BACKGROUND: An adult population pharmacokinetic/pharmacodynamic (PK/PD) model for the antiseizure medication (ASM) brivaracetam (BRV) was previously extended to children aged 4-16 years by using a pediatric BRV population PK model. Effects were scaled using information from a combined adult-pediatric PK/PD model of a related ASM, levetiracetam (LEV). OBJECTIVE: To scale an existing adult population PK/PD model for BRV to children aged 1 month to < 4 years using information from a combined adult-pediatric PK/PD model for LEV, and to predict the effective dose of BRV in children aged 1 month to < 4 years using the adult BRV PK/PD model modified for the basal seizure rate in children. MATERIAL AND METHODS: An existing adult population PK/PD model for BRV was scaled to children aged from 1 month to < 4 years using information from a combined adult-pediatric PK/PD model for LEV, an ASM binding to the same target protein as BRV. An existing adult-pediatric PK/PD model for LEV was extended using data from UCB study N01009 (NCT00175890) to include children as young as 1 month of age. The BRV population PK model was updated with data up to 180 days after first administration from BRV pediatric studies N01263 (NCT00422422) and N01266 (NCT01364597). PK and PD simulations for BRV were performed for a range of mg/kg doses to predict BRV effect in pediatric participants, and to provide dosing recommendations. RESULTS: The extended adult-pediatric LEV PK/PD model was able to describe the adult and pediatric data using the same PD model parameters in adults and children and supported the extension of the adult BRV PK/PD model to pediatric patients aged 1 month to < 4 years. Simulations predicted exposures similar to adults receiving BRV 100 mg twice daily (b.i.d.), when using 3 mg/kg b.i.d. for weight < 10 kg, 2.5 mg/kg b.i.d. for weight ≥ 10 kg and < 20 kg, and 2 mg/kg b.i.d. for weight ≥ 20 kg in children aged 1 month to < 4 years. PK/PD simulations show that maximum BRV response is expected to occur with 2-3 mg/kg b.i.d. dosing of BRV in children aged 1 month to < 4 years, with an effective dose of 1 mg/kg b.i.d. for some participants. CONCLUSION: Development of an adult-pediatric BRV PK/PD model allowed characterization of the exposure-response relationship of BRV in children aged 1 to < 4 years, providing a maximal dose allowance based on weight.


Subject(s)
Anticonvulsants , Levetiracetam , Pyrrolidinones , Humans , Levetiracetam/pharmacokinetics , Levetiracetam/pharmacology , Anticonvulsants/pharmacokinetics , Anticonvulsants/administration & dosage , Child, Preschool , Pyrrolidinones/pharmacokinetics , Pyrrolidinones/pharmacology , Infant , Child , Male , Female , Adolescent , Adult , Dose-Response Relationship, Drug , Epilepsy/drug therapy , Young Adult , Infant, Newborn , Age Factors , Seizures/drug therapy
4.
Epilepsia ; 65(5): 1285-1293, 2024 May.
Article in English | MEDLINE | ID: mdl-38400747

ABSTRACT

OBJECTIVE: Levetiracetam (LEV) is an antiseizure medication that is mainly excreted by the kidneys. Due to its low teratogenic risk, LEV is frequently prescribed for women with epilepsy (WWE). Physiological changes during gestation affect the pharmacokinetic characteristics of LEV. The goal of our study was to characterize the changes in LEV clearance during pregnancy and the postpartum period, to better plan an LEV dosing paradigm for pregnant women. METHODS: This retrospective observational study incorporated a cohort of women who were followed up at the epilepsy in pregnancy clinic at Tel Aviv Sourasky Medical Center during the years 2020-2023. Individualized target concentrations of LEV and an empirical postpartum taper were used for seizure control and to reduce toxicity likelihood. Patient visits took place every 1-2 months and included a review of medication dosage, trough LEV blood levels, week of gestation and LEV dose at the time of level measurement, and seizure diaries. Total LEV concentration/dose was calculated based on LEV levels and dose as an estimation of LEV clearance. RESULTS: A total of 263 samples were collected from 38 pregnant patients. We observed a decrease in LEV concentration/dose (C/D) as the pregnancy progressed, followed by an abrupt postpartum increase. Compared to the 3rd trimester, the most significant C/D decrease was observed at the 1st trimester (slope = .85), with no significant change in the 2nd trimester (slope = .11). A significant increase in C/D occurred postpartum (slope = 5.23). LEV dose was gradually increased by 75% during pregnancy compared to preconception. Average serum levels (µg/mL) decreased during pregnancy. During the postpartum period, serum levels increased, whereas the LEV dose was decreased by 24%, compared to the 3rd trimester. SIGNIFICANCE: LEV serum level monitoring is essential for WWE prior to and during pregnancy as well as postpartum. Our data contribute to determining a rational treatment and dosing paradigm for LEV use during both pregnancy and the postpartum period.


Subject(s)
Anticonvulsants , Drug Monitoring , Epilepsy , Levetiracetam , Pregnancy Complications , Humans , Female , Levetiracetam/therapeutic use , Levetiracetam/administration & dosage , Levetiracetam/pharmacokinetics , Levetiracetam/blood , Pregnancy , Anticonvulsants/pharmacokinetics , Anticonvulsants/blood , Anticonvulsants/therapeutic use , Anticonvulsants/administration & dosage , Drug Monitoring/methods , Adult , Retrospective Studies , Pregnancy Complications/drug therapy , Pregnancy Complications/blood , Epilepsy/drug therapy , Epilepsy/blood , Postpartum Period , Young Adult
5.
Eur J Drug Metab Pharmacokinet ; 47(5): 667-676, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35761145

ABSTRACT

BACKGROUND AND OBJECTIVE: Nonadherence to levetiracetam (LEV) use can result in subtherapeutic concentrations and increase the risk of the occurrence of seizures. The impact of missing LEV doses on its pharmacokinetics and evidence of the appropriate remedial dose is lacking. This study has determined the influence of missed LEV doses on its pharmacokinetics and has explored the appropriate remedial dosage regimens. METHODS: Monte Carlo simulation was used to assess the impacts of different remedial dosage regimens on LEV concentrations. Simulated LEV concentrations outside the individual therapeutic range were calculated for the compliance scenario and for each of the remedial dosage regimens. The percentage of deviation from the full compliance scenario was also calculated. The regimen with the lowest percentage of deviation was considered the most appropriate. RESULTS: The suitable LEV remedial dose varied across the delay times. For one missed dose, a remedial regimen with a regular dose followed by the usual dose was suitable for a delay time of less than 6 h, while a replacement with a regular dose followed by a partial dose appeared to be appropriate for a delay time of 6 h and longer. This was justified based on the concerns of LEV toxicity when the remedial dose is close to the next scheduled dose. For two consecutive missed doses, a remedial dose with one and a half of the regular dose was suitable if the gap between that and the next dose was greater than 6 h. CONCLUSIONS: The appropriate remedial dosage regimen for one and two consecutive missed doses of LEV have been proposed. These remedial regimens, however, should be applied with clinicians' judgment based on the clinical status of the patients.


Subject(s)
Anticonvulsants , Piracetam , Anticonvulsants/pharmacokinetics , Computer Simulation , Humans , Levetiracetam/pharmacokinetics , Levetiracetam/therapeutic use , Monte Carlo Method , Piracetam/pharmacokinetics , Seizures/drug therapy
6.
Curr Rev Clin Exp Pharmacol ; 17(2): 122-134, 2022.
Article in English | MEDLINE | ID: mdl-33622228

ABSTRACT

BACKGROUND: The use of levetiracetam (LEV) has been increasing, given its favorable pharmacokinetic profile. Numerous population pharmacokinetic studies for LEV have been conducted. However, there are some discrepancies regarding factors affecting its pharmacokinetic variability. Therefore, this systematic review aimed to summarize significant predictors for LEV pharmacokinetics as well as the need for dosage adjustments. METHODS: We performed a systematic search for population pharmacokinetic studies of LEV conducted using a nonlinear-mixed effect approach from PubMed, Scopus, CINAHL Complete, and Science Direct databases from their inception to March 2020. Information on study design, model methodologies, significant covariate-parameter relationships, and model evaluation was extracted. The quality of the reported studies was also assessed. RESULTS: A total of 16 studies were included in this review. Only two studies were conducted with a two-compartment model, while the rest were performed with a one-compartment structure. Bodyweight and creatinine clearance were the two most frequently identified covariates on LEV clearance (CLLEV). Additionally, postmenstrual age (PMA) or postnatal age (PNA) were significant predictors for CLLEV in neonates. Only three studies externally validated the models. Two studies conducted pharmacodynamic models for LEV with relatively small sample size. CONCLUSION: Significant predictors for LEV pharmacokinetics are highlighted in this review. For future research, a population pharmacokinetic-pharmacodynamic model using a larger sample size should be conducted. From a clinical perspective, the published models should be externally evaluated before clinical implementation.


Subject(s)
Anticonvulsants , Research Design , Anticonvulsants/therapeutic use , Body Weight , Humans , Infant, Newborn , Kinetics , Levetiracetam/pharmacokinetics
7.
PLoS One ; 16(11): e0259400, 2021.
Article in English | MEDLINE | ID: mdl-34752482

ABSTRACT

BACKGROUND: The use of enteral nutrients plays a highly important role in accurate nutrition management, but limited information is currently available on the cautionary points of semi-solid enteral nutrients. AIM: In this study, we examined whether the pharmacokinetic profiles of sodium valproate (SVA), levetiracetam (LEV), and carbamazepine (CBZ) are affected by altering the dosing time of RACOL®-NF Semi Solid for Enteral Use (RASS), a prescribed semi-solid formula. We also investigated whether the pharmacokinetic interaction observed in this study can be avoided by staggered dosing of the chemical drug and semi-solid enteral nutrient. METHODS: The plasma concentration of SVA, LEV and CBZ after oral administration was measured by LC-MS/MS method. RESULTS: There was no difference in pharmacokinetic characteristics of SVA and LEV when the dosing time of RASS was altered. On the other hand, the plasma concentration of CBZ after oral administration at all sampling points decreased with the extension of the dosing time of RASS, which was consistent with the Cmax and AUC. However, no significant difference was observed in the pharmacokinetic profiles or parameters of CBZ between the short-term and long-term RASS dosing groups by prolonging the administered interval of CBZ and RASS for 2 hr. CONCLUSION: We concluded that the pharmacokinetic profiles of CBZ, but not SVA and LEV, after its oral administration are affected by the dosing time of RASS, but staggered administration of CBZ and RASS prevented their interaction.


Subject(s)
Anticonvulsants/pharmacokinetics , Nutrients/chemistry , Administration, Oral , Animals , Anticonvulsants/blood , Anticonvulsants/chemistry , Area Under Curve , Carbamazepine/blood , Carbamazepine/chemistry , Carbamazepine/pharmacokinetics , Chromatography, High Pressure Liquid , Drug Compounding/methods , Half-Life , Levetiracetam/blood , Levetiracetam/chemistry , Levetiracetam/pharmacokinetics , ROC Curve , Rats , Rats, Sprague-Dawley , Tandem Mass Spectrometry , Valproic Acid/blood , Valproic Acid/chemistry , Valproic Acid/pharmacokinetics
8.
J Clin Pharmacol ; 61(10): 1366-1375, 2021 10.
Article in English | MEDLINE | ID: mdl-33997989

ABSTRACT

Levetiracetam is a broad-spectrum antiepileptic drug that exhibits high interindividual variability in serum concentrations in children. A population pharmacokinetic approach can be used to explain this variability and optimize dosing schemes. The objectives are to identify the best predictive population pharmacokinetic model for children and to evaluate recommended doses using simulations and Bayesian forecasting. A validation cohort included children treated with levetiracetam who had a serum drug concentration assayed during therapeutic drug monitoring. We assessed the predictive performance of all the population pharmacokinetic models published in the literature using mean prediction errors, root mean squared errors, and visual predictive checks. A population model was finally constructed on the data, and dose simulations were performed to evaluate doses. We included 267 levetiracetam concentrations ranging from 2 to 69 mg/L from 194 children in the validation cohort. Six published models were externally evaluated. Most of the models underestimated the variability of our population. A 1-compartment model with first-order absorption and elimination with allometric scaling was finally fitted on our data. In our cohort, 57% of patients had a trough concentration <12 mg/L and 12% <5 mg/L. To reach a trough concentration >5 mg/L, doses ≥30 mg/kg/d for patients ≤50 kg and ≥2000 mg/d for patients >50 kg are required. In our population, a high percentage of children had low trough concentrations. Our population pharmacokinetic model could be used for therapeutic drug monitoring of levetiracetam in children.


Subject(s)
Anticonvulsants/pharmacokinetics , Levetiracetam/pharmacokinetics , Models, Biological , Adolescent , Age Factors , Anticonvulsants/administration & dosage , Anticonvulsants/blood , Bayes Theorem , Body Weight , Child , Child, Preschool , Creatinine/blood , Dose-Response Relationship, Drug , Drug Monitoring , Drug Therapy, Combination , Female , Glomerular Filtration Rate , Humans , Infant , Levetiracetam/administration & dosage , Levetiracetam/blood , Male , Reproducibility of Results , Sex Factors
9.
Ther Drug Monit ; 43(3): 394-400, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33851939

ABSTRACT

BACKGROUND: Drug concentrations of antiepileptic drugs (AEDs) are routinely determined from blood serum or plasma at trough levels (before intake of morning dose). In capillary blood collection, blood is taken from the fingertip with the aid of a disposable tool and dried on absorbent material. The volumetric absorptive microsampling technique offers several advantages over the use of filter paper cards. The aim of this study was to determine conversion factors for the estimation of AED serum concentrations from capillary blood concentrations. METHODS: Venous and capillary blood samples were collected from adult inpatients with epilepsy who were treated with lacosamide (LCM, n = 30), lamotrigine (LTG, n = 40), and/or levetiracetam (LEV, n = 36). A validated liquid chromatography-mass spectrometry (LC-MS) method for dried blood samples for these AEDs was compared with routine serum laboratory methods. Method agreement was evaluated using different regression techniques, and the conversion factors were calculated. RESULTS: Regression analyses revealed a linear relationship between serum and capillary blood concentrations for all 3 AEDs (r ≥ 0.95). For LTG, the regression intercept was significantly different from 0, indicating that the relationship was linear, but not necessarily proportional. Although LEV and LCM concentrations tended to be lower in capillary blood than in serum (mean ratio of serum concentration to capillary blood concentration: 1.14 and 1.22, respectively), LTG concentrations were higher in capillary blood (mean ratio = 0.85). CONCLUSIONS: The estimation of serum concentrations from measured capillary blood concentrations is feasible for LCM, LTG, and LEV. A simple ratio approach using the mean ratio and Passing-Bablok regression showed the best results for all 3 AEDs. The volumetric absorptive microsampling technique facilitates the quantitative sample collection of capillary blood and overcomes the drawbacks associated with the classical dried blood spot technique.


Subject(s)
Anticonvulsants/pharmacokinetics , Drug Monitoring , Lacosamide/pharmacokinetics , Lamotrigine/pharmacokinetics , Levetiracetam/pharmacokinetics , Adult , Anticonvulsants/blood , Dried Blood Spot Testing , Humans , Lacosamide/blood , Lamotrigine/blood , Levetiracetam/blood , Reference Values , Serum
10.
Clin Transl Sci ; 14(4): 1444-1451, 2021 07.
Article in English | MEDLINE | ID: mdl-33742783

ABSTRACT

Estimating early exposure of drugs used for the treatment of emergent conditions is challenging because blood sampling to measure concentrations is difficult. The objective of this work was to evaluate predictive performance of two early concentrations and prior pharmacokinetic (PK) information for estimating early exposure. The performance of a modeling approach was compared with a noncompartmental analysis (NCA). A simulation study was performed using literature-based models for phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA). These models were used to simulate rich concentration-time profiles from 0 to 2 h. Profiles without residual unexplained variability (RUV) were used to obtain the true partial area under the curve (pAUC) until 2 h after the start of drug infusion. From the profiles with the RUV, two concentrations per patient were randomly selected. These concentrations were analyzed under a population model to obtain individual population PK (PopPK) pAUCs. The NCA pAUCs were calculated using a linear trapezoidal rule. Percent prediction errors (PPEs) for the PopPK pAUCs and NCA pAUCs were calculated. A PPE within ±20% of the true value was considered a success and the number of successes was obtained for 100 simulated datasets. For PHT, LEV, and VPA, respectively, the median value of the success statistics obtained using the PopPK approach of 81%, 92%, and 88% were significantly higher than the 72%, 80%, and 67% using the NCA approach (p < 0.05; Mann-Whitney U test). This study provides a means by which early exposure can be estimated with good precision from two concentrations and a PopPK approach. It can be applied to other settings in which early exposures are of interest.


Subject(s)
Blood Specimen Collection/methods , Drug Monitoring/methods , Models, Biological , Adolescent , Adult , Area Under Curve , Biological Variation, Population , Child , Child, Preschool , Computer Simulation , Emergency Treatment , Female , Healthy Volunteers , Humans , Levetiracetam/administration & dosage , Levetiracetam/blood , Levetiracetam/pharmacokinetics , Male , Middle Aged , Phenytoin/administration & dosage , Phenytoin/blood , Phenytoin/pharmacokinetics , Valproic Acid/administration & dosage , Valproic Acid/blood , Valproic Acid/pharmacokinetics , Young Adult
11.
Epilepsia ; 62(2): 285-302, 2021 02.
Article in English | MEDLINE | ID: mdl-33426641

ABSTRACT

The safety of switching between generic products of antiseizure medications (ASMs) continues to be a hot topic in epilepsy management. The main reason for concern relates to the uncertainty on whether, and when, two generics found to be bioequivalent to the same brand (reference) product are bioequivalent to each other, and the risk of a switch between generics resulting in clinically significant changes in plasma ASM concentrations. This article addresses these concerns by discussing the distinction between bioequivalence and statistical testing for significant difference, the importance of intra-subject variability in interpreting bioequivalence studies, the stricter regulatory bioequivalence requirements applicable to narrow-therapeutic-index (NTI) drugs, and the extent by which currently available generic products of ASMs comply with such criteria. Data for 117 oral generic products of second-generation ASMs approved in Europe by the centralized, mutual recognition or decentralized procedure were analyzed based on a review of publicly accessible regulatory assessment reports. The analysis showed that for 99% of generic products assessed (after exclusion of gabapentin products), the 90% confidence intervals (90% CIs) of geometric mean ratios (test/reference) for AUC (area under the drug concentration vs time curve) were narrow and wholly contained within the acceptance interval (90%-111%) applied to NTI drugs. Intra-subject variability for AUC was <10% for 53 (88%) of the 60 products for which this measure was reported. Many gabapentin generics showed broader, 90% CIs for bioequivalence estimates, and greater intra-subject variability, compared with generics of other ASMs. When interpreted within the context of other available data, these results suggest that any risk of non-bioequivalence between these individual generic products is small, and that switches across these products are not likely to result in clinically relevant changes in plasma drug exposure. The potential for variability in exposure when switching across generics is likely to be greatest for gabapentin.


Subject(s)
Anticonvulsants/pharmacokinetics , Therapeutic Equivalency , Area Under Curve , Biological Variation, Individual , Dibenzazepines/pharmacokinetics , Drug Substitution , Drugs, Generic , Europe , Gabapentin/pharmacokinetics , Humans , Lacosamide/pharmacokinetics , Lamotrigine/pharmacokinetics , Levetiracetam/pharmacokinetics , Oxcarbazepine/pharmacokinetics , Pregabalin/pharmacokinetics , Topiramate/pharmacokinetics , Vigabatrin/pharmacokinetics , Zonisamide/pharmacokinetics
12.
J Clin Pharmacol ; 61(6): 763-768, 2021 06.
Article in English | MEDLINE | ID: mdl-33336359

ABSTRACT

Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus. However, limited information is available regarding LEV and VPA concentrations following high intravenous doses, particularly in young children. The Established Status Epilepticus Treatment Trial, a blinded, comparative effectiveness study of FOS, LEV, and VPA for benzodiazepine-refractory status epilepticus provided an opportunity to investigate early drug concentrations. Patients aged ≥2 years who continued to seizure despite receiving adequate doses of benzodiazepines were randomly assigned to FOS, LEV, or VPA infused over 10 minutes. A sparse blood-sampling approach was used, with up to 2 samples collected per patient within 2 hours following drug administration. The objective of this work was to report early drug exposure of PHT, LEV, and VPA and plasma protein binding of PHT and VPA. Twenty-seven children with median (interquartile range) age of 4 (2.5-6.5) years were enrolled. The total plasma concentrations ranged from 69 to 151.3 µg/mL for LEV, 11.3 to 26.7 µg/mL for PHT and 126 to 223 µg/mL for VPA. Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA. This is the first report in young children of LEV concentrations with convulsive status epilepticus as well as VPA concentrations after a 40 mg/kg dose. Several challenges limited patient enrollment and blood sampling. Additional studies with a larger sample size are required to evaluate the exposure-response relationships in this emergent condition.


Subject(s)
Anticonvulsants/pharmacokinetics , Anticonvulsants/therapeutic use , Status Epilepticus/drug therapy , Anticonvulsants/administration & dosage , Benzodiazepines/therapeutic use , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Humans , Infusions, Intravenous , Levetiracetam/administration & dosage , Levetiracetam/pharmacokinetics , Male , Phenytoin/administration & dosage , Phenytoin/analogs & derivatives , Phenytoin/pharmacokinetics , Protein Binding , Valproic Acid/administration & dosage , Valproic Acid/pharmacokinetics
13.
Ann N Y Acad Sci ; 1480(1): 219-232, 2020 11.
Article in English | MEDLINE | ID: mdl-32961584

ABSTRACT

Organophosphorus (OP) compounds are chemical threat agents and are irreversible inhibitors of the enzyme acetylcholinesterase that lead to a hypercholinergic response that could include status epilepticus (SE). SE particularly targets the heart and brain and despite existing therapies, it is still associated with significant mortality and morbidity. Here, we investigated the effect of intramuscular (i.m.) adjunct therapy consisting of atenolol (AT) and levetiracetam (LV) when administered after paraoxon (POX)-induced SE. The combination therapy was administered twice daily for 2, 7, or 14 days. POX exposure in rats produced rapid SE onset that was treated with atropine, pralidoxime chloride, and midazolam. Here, AT + LV therapy produced significant reductions in POX SE mortality assessed at 30 days post-SE. AT + LV therapy exhibited muscle pathology inflammation scores that were not significantly different from saline-treated controls. Pharmacokinetic analyses revealed that the i.m. route achieved faster and stabler plasma therapeutic levels for both AT and LV under OP SE conditions compared with oral administrations. Our data provide evidence of the safety and efficacy of i.m. AT + LV therapy for reducing mortality following POX SE.


Subject(s)
Atenolol , Levetiracetam , Paraoxon/adverse effects , Status Epilepticus , Administration, Oral , Animals , Atenolol/pharmacokinetics , Atenolol/pharmacology , Injections, Intramuscular , Levetiracetam/pharmacokinetics , Levetiracetam/pharmacology , Male , Paraoxon/pharmacology , Rats , Rats, Sprague-Dawley , Status Epilepticus/chemically induced , Status Epilepticus/drug therapy , Status Epilepticus/metabolism , Status Epilepticus/physiopathology
14.
Ther Drug Monit ; 42(5): 744-753, 2020 10.
Article in English | MEDLINE | ID: mdl-32558674

ABSTRACT

BACKGROUND: The use of therapeutic drug monitoring (TDM) for antiseizure medications (ASMs) may contribute to treatment optimization in individual patients. This study included patients with Dravet syndrome as they often require close monitoring because of polypharmacy with various ASMs. The aim was to use long-term TDM to investigate pharmacokinetic variability of ASMs in these patients. METHODS: Retrospective data from patients with Dravet syndrome were collected from the TDM database at the Section for Clinical Pharmacology, National Center for Epilepsy in Norway (2008-2018). Concentration/(dose/kg)ratios (C/D ratios) were calculated for the ASMs and the concentration (C/C ratio) for N-desmethylclobazam. In patients with at least 3 measurements, the CV for C/D ratios for intrapatient and interpatient variability was calculated. RESULTS: Fifty-three patients (30 male patients/23 female patients) between 2 and 50 years of age (mean, 16 years) were included. Pharmacokinetic variability of the total number of measurements of valproate (n = 417), clobazam and N-desmethylclobazam (n = 328), and levetiracetam (n = 238) was determined. Interpatient variability was more pronounced than intrapatient variability (coefficient of variations: valproate, 65% vs. 24%; levetiracetam, 71% vs. 27%; and clobazam/N-desmethylclobazam, 47%/77% vs. 35%/55%) (P < 0.01). Comedication with stiripentol (n = 16) increased the C/D ratio of valproate by 63% and of clobazam by 133% and the C/C ratio of N-desmethylclobazam/clobazam by 104% (P < 0.05). Younger age also contributed to pharmacokinetic variability. CONCLUSIONS: Long-term TDM revealed extensive variability in serum concentrations over time; the variability was lowest for levetiracetam, moderate for valproate, and highest for clobazam. Pharmacokinetic variability and interactions can thus be identified and adjusted to facilitate decision making to achieve the optimal treatment outcome.


Subject(s)
Clobazam/blood , Clobazam/pharmacokinetics , Epilepsies, Myoclonic/blood , Levetiracetam/blood , Levetiracetam/pharmacokinetics , Valproic Acid/blood , Valproic Acid/pharmacokinetics , Adolescent , Adult , Anticonvulsants/blood , Anticonvulsants/pharmacokinetics , Benzodiazepines/blood , Benzodiazepines/pharmacokinetics , Child , Child, Preschool , Clobazam/therapeutic use , Dioxolanes/blood , Dioxolanes/pharmacokinetics , Drug Monitoring/methods , Epilepsies, Myoclonic/drug therapy , Epilepsy/blood , Epilepsy/drug therapy , Female , Humans , Levetiracetam/therapeutic use , Male , Middle Aged , Norway , Retrospective Studies , Valproic Acid/therapeutic use , Young Adult
15.
Xenobiotica ; 50(9): 1090-1100, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32208795

ABSTRACT

This study aimed to evaluate the pharmacokinetics and pharmacodynamics of oral levetiracetam therapy in drug refractory adult epileptic outpatients, as well as factors affecting them. Concentration-time data were collected at steady state, while seizure recurrence was monitored for 13 months. Non-linear mixed effects modeling was applied, and covariates assessed included weight, height, age, daily dose and creatinine clearance.Plasma concentrations of levetiracetam were best described by a one-compartment pharmacokinetic model (V/F = 34.7 L) with first-order absorption (ka = 0.616 h-1) and clearance (CL/F = 3.26 L/h). Patient's CrCL was found to significantly affect levetiracetam clearance (beta = 0.795). Time to seizure occurrence followed an exponential distribution and the mean time to seizure occurrence was estimated Te = 22.08 days. Seizure rate per month followed a Poisson distribution, while mean seizure rate per month was estimated λ = 1.33. Daily dose significantly affected the mean estimated time to seizure (beta = -2.2) and the mean monthly seizure rate (beta = 2.27) in a reverse way. Using discrete time Markov chains, it was shown that the transition probability from focal seizures to focal to bilateral tonic-clonic is significantly altered in relation to patient's CrCL.Simulations showed that dose should be adjusted in relation to CrCL, while low doses of levetiracetam are more effective for seizure control. Modeling and simulation in every-day clinical practice may provide significant information for the optimization of seizure control using well-known agents.


Subject(s)
Anticonvulsants/pharmacokinetics , Levetiracetam/pharmacokinetics , Adult , Body Weight , Epilepsy , Female , Humans , Male
16.
Clin Transl Sci ; 13(5): 950-959, 2020 09.
Article in English | MEDLINE | ID: mdl-32223067

ABSTRACT

Limited data exist on the effect of continuous renal replacement therapy (CRRT) methods on anti-epileptic drug pharmacokinetics (PK). This prospective practice-based PK study aims to assess the impact of continuous venovenous hemofiltration (CVVH), a modality of CRRT, on levetiracetam PK in critically ill patients and to derive individualized dosing recommendations. Eleven patients receiving oral or intravenous levetiracetam and CVVH in various intensive care units at a large academic medical center were enrolled to investigate the need for dosing adjustments. Prefilter, postfilter, and ultrafiltrate samples were obtained before dosing, after the completion of the infusion or 1-hour postoral dose, and up to 6 additional time points postinfusion or postoral administration. Patient-specific blood and ultrafiltrate flow rates and laboratory values were also collected at the time of sampling. The average sieving coefficient (SC) for levetiracetam was 0.89 ± 0.1, indicating high filter efficiency. Six of the 11 patients experienced concentrations outside the reported therapeutic range (12-46 mg/L). The average volume of distribution was 0.73 L/kg. CVVH clearance contributes a major fraction of the total levetiracetam clearance (36-73%) in neurocritically ill patients. The average bias and precision of the estimated vs. observed total clearance value was ~ 10.6% and 21.5%. Major dose determinants were identified to be SC and effluent flow rate. Patients with higher ultrafiltrate rates will have increased drug clearance and, therefore, will require higher doses in order to match exposures seen in patients with normal renal function.


Subject(s)
Acute Kidney Injury/therapy , Anticonvulsants/pharmacokinetics , Continuous Renal Replacement Therapy/adverse effects , Levetiracetam/pharmacokinetics , Seizures/drug therapy , Academic Medical Centers , Acute Kidney Injury/blood , Acute Kidney Injury/physiopathology , Administration, Intravenous , Administration, Oral , Aged , Anticonvulsants/administration & dosage , Area Under Curve , Critical Illness/therapy , Dose-Response Relationship, Drug , Female , Glomerular Filtration Rate/physiology , Humans , Intensive Care Units , Levetiracetam/administration & dosage , Male , Middle Aged , Prospective Studies , Renal Elimination/physiology
17.
Curr Drug Metab ; 21(2): 126-131, 2020.
Article in English | MEDLINE | ID: mdl-32067615

ABSTRACT

BACKGROUND: Clobazam (CLBZ) metabolized primarily by Cytochrome P-450 isoenzyme CYP3A4 than with CYP2C19, Whereas Levetiracetam (LEV) is metabolized by hydrolysis of the acetamide group. Few CYP enzymes are inhibited by Proton Pump Inhibitors (PPIs) Pantoprazole, Esomeprazole, and Rabeprazole in different extents that could affect drug concentrations in blood. The aim of the present study was to evaluate the effect of these PPIs on the plasma concentrations of LEV and CLBZ. METHODS: Blood samples from 542 patients were included out of which 343 were male and 199 were female patients and were categorized as control and test. Plasma samples analyzed using an HPLC-UV method. Plasma concentrations were measured and compared to those treated and those not treated with PPIs. One way ANOVA and games Howell post hoc test used by SPSS 20 software. RESULTS: CLBZ concentrations were significantly 10 folds higher in patients treated with Pantoprazole (P=0.000) and 07 folds higher in patients treated with Esmoprazole and Rabeprazole (P=0.00). Whereas plasma concentration of LEV control group has no statistical and significant difference when compared to pantoprazole (P=0.546) and with rabeprazole and esomeprazole was P=0.999. CONCLUSION: The effect of comedication with PPIs on the plasma concentration of clobazam is more pronounced for pantoprazole to a greater extent when compared to esomeprazole and rabeprazole. When pantoprazole is used in combination with clobazam, dose reduction of clobazam should be considered, or significance of PPIs is seen to avoid adverse effects.


Subject(s)
Anticonvulsants/pharmacokinetics , Clobazam/pharmacokinetics , Esomeprazole/pharmacology , Levetiracetam/pharmacokinetics , Pantoprazole/pharmacology , Proton Pump Inhibitors/pharmacology , Rabeprazole/pharmacology , Anticonvulsants/blood , Clobazam/blood , Drug Interactions , Female , Humans , Levetiracetam/blood , Male
18.
Pol J Vet Sci ; 23(4): 491-494, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33480487

ABSTRACT

Canine status epilepticus (CSE) is characterized by epileptic seizures that are longer than 5 min or more than one seizure with incomplete recovery. Currently, diazepam suppositories are generally prescribed for CSE. Levetiracetam (LEV) is one of the newest antiepileptic drugs currently available. This study compared the pharmacokinetics of intragastric and intrarectal administration in oral formula of LEV in four healthy beagles as a reference data when the owner administers levetiracetam to dogs by himself at home. Blood for measuring plasma LEV concen- trations was collected 0, 30, 60, 90, 120, 240, 360, and 540 min after LEV administration. The time to reach the maximum plasma concentration (Tmax) was markedly shorter with intra- rectal administration (45±26 min) than with intragastric administration (270±99 min). Intrarectal administration of LEV tablets could be an effective option for treating canine seizures although it might be a limit for treating CSE because the absorption rate is not fast enough.


Subject(s)
Anticonvulsants/pharmacokinetics , Dogs/metabolism , Levetiracetam/pharmacokinetics , Administration, Oral , Administration, Rectal , Animals , Anticonvulsants/administration & dosage , Anticonvulsants/blood , Area Under Curve , Dogs/blood , Female , Levetiracetam/administration & dosage , Levetiracetam/blood , Male
20.
J Clin Pharmacol ; 60(3): 324-330, 2020 03.
Article in English | MEDLINE | ID: mdl-31729053

ABSTRACT

High-dose methotrexate (HDMTX) is a commonly used treatment for hematologic malignancies involving the central nervous system. Two case reports described possible delayed methotrexate clearance in patients receiving concurrent levetiracetam, while a retrospective cohort study did not find this association. The objective of this single-center, retrospective case-control study of 121 patients who received their first cycle of HDMTX was to investigate the association between HDMTX clearance time and concomitant levetiracetam use. The most common diagnosis was primary central nervous system lymphoma (47.9%). The mean HDMTX dose was 4601 mg/m2 (standard deviation [SD], 2052.6 mg/m2 ). Concurrent levetiracetam was administered in 30 of 121 patients (24.8%), with a mean total daily levetiracetam dose of 1434.4 mg (SD, 622.9 mg; range, 900-3000 mg). Baseline characteristics were similar between patients who received concomitant levetiracetam and those who did not. The mean time to methotrexate clearance was 82.5 hours (SD, 51.2; 95% confidence interval, 69.4-95.7) in the concomitant levetiracetam group and 72.4 hours (SD, 31.2; 95% confidence interval, 61.7-83.0) in the nonlevetiracetam group, which was not significantly different (P > .05), even in the subgroup receiving methotrexate doses >3500 mg/m2 . Grade 3 or higher toxicity occurred in 33.3% of the concomitant levetiracetam group and in 34.1% of nonconcomitant levetiracetam patients. This study, which, to our knowledge, is the first examining levetiracetam effect on only the first dose of HDMTX, supports the larger retrospective study finding no significant effect of levetiracetam on HDMTX clearance time, and suggests that administering concomitant levetiracetam does not affect HDMTX toxicity.


Subject(s)
Anticonvulsants/pharmacokinetics , Antimetabolites, Antineoplastic/adverse effects , Antimetabolites, Antineoplastic/pharmacokinetics , Hematologic Neoplasms/drug therapy , Levetiracetam/pharmacokinetics , Methotrexate/adverse effects , Methotrexate/pharmacokinetics , Adolescent , Adult , Aged , Aged, 80 and over , Anticonvulsants/administration & dosage , Antimetabolites, Antineoplastic/administration & dosage , Central Nervous System Neoplasms/drug therapy , Drug Administration Schedule , Drug Interactions , Female , Humans , Levetiracetam/administration & dosage , Male , Methotrexate/administration & dosage , Middle Aged , Retrospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...